PolyPeptide Group (PPGN.SW) Stock Price

PolyPeptide Group Price

SIX·CLOSED
47.04EUR+0.07 (+0.14 %)
Market closed

Revenue has compounded at 11.4% per year over the past 7 years to 349.56 M EUR. Earnings per share have declined at 25.0% per year over the last 4 years. PolyPeptide Group's net margin stands at -5.7%, down from 16.9% several years earlier. PolyPeptide Group currently offers a dividend yield of about 0.64%. The payout ratio is around 136% of earnings. Analysts set a median price target of 39.85 EUR, implying 15.3% below the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 95% above its 52-week low.

PolyPeptide Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of PolyPeptide Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PolyPeptide Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PolyPeptide Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

PolyPeptide Group Stock Price History
DatePolyPeptide Group Price
8/10/202647.04 EUR
8/7/202646.97 EUR
8/6/202647.11 EUR
8/5/202647.03 EUR
8/4/202647.11 EUR
7/31/202646.93 EUR
7/30/202647.08 EUR
7/29/202647.03 EUR
7/28/202647.07 EUR
7/27/202647.07 EUR
7/24/202647.11 EUR
7/23/202647.22 EUR
7/22/202647.22 EUR
7/21/202647.41 EUR
7/20/202647.36 EUR
7/17/202646.83 EUR
7/16/202649.05 EUR
7/15/202650.67 EUR
7/14/202651.14 EUR
7/13/202649.42 EUR
7/10/202649.84 EUR
7/9/202651.02 EUR
7/8/202650.12 EUR
7/7/202651.13 EUR
7/6/202653.69 EUR
7/3/202652.36 EUR
7/2/202652.44 EUR
7/1/202652.30 EUR
6/30/202651.02 EUR
6/29/202649.40 EUR
6/26/202650.41 EUR
6/25/202648.31 EUR
6/24/202645.95 EUR
6/23/202642.75 EUR
6/22/202641.88 EUR
6/19/202641.80 EUR
6/18/202639.46 EUR
6/17/202639.19 EUR
6/16/202639.39 EUR
6/15/202636.56 EUR
6/12/202636.57 EUR
6/11/202637.28 EUR
6/10/202637.65 EUR
6/9/202638.47 EUR
6/8/202639.61 EUR
6/5/202640.91 EUR
6/4/202640.57 EUR
6/3/202641.45 EUR
6/2/202642.10 EUR
6/1/202642.40 EUR
5/29/202641.24 EUR
5/28/202641.10 EUR
5/27/202642.03 EUR
5/26/202642.36 EUR
5/22/202641.40 EUR
5/21/202641.28 EUR
5/20/202642.19 EUR
5/19/202641.10 EUR
5/18/202640.44 EUR
5/15/202640.77 EUR
5/13/202641.29 EUR
5/12/202641.13 EUR
5/11/202642.55 EUR
5/8/202642.98 EUR
5/7/202644.46 EUR
5/6/202643.75 EUR
5/5/202643.47 EUR
5/4/202642.66 EUR
4/30/202641.62 EUR
4/29/202640.42 EUR
4/28/202638.51 EUR
4/27/202638.67 EUR
4/24/202638.95 EUR
4/23/202637.58 EUR
4/22/202637.86 EUR
4/21/202638.18 EUR
4/20/202638.62 EUR
4/17/202639.55 EUR
4/16/202639.76 EUR
4/15/202640.64 EUR
4/14/202640.91 EUR
4/13/202639.16 EUR
4/10/202634.53 EUR
4/9/202632.02 EUR
4/8/202632.62 EUR
4/7/202632.46 EUR
4/2/202632.51 EUR
4/1/202632.22 EUR
3/31/202630.76 EUR
3/30/202628.97 EUR
3/27/202628.64 EUR
3/26/202629.67 EUR
3/25/202629.02 EUR
3/24/202626.85 EUR
3/23/202626.69 EUR
3/20/202626.69 EUR
3/19/202627.29 EUR
3/18/202628.23 EUR
3/17/202628.23 EUR
3/16/202626.75 EUR
3/13/202626.64 EUR
3/12/202629.21 EUR
3/11/202626.86 EUR
3/10/202627.51 EUR
3/9/202626.80 EUR
3/6/202626.20 EUR
3/5/202627.86 EUR
2/27/202628.10 EUR
2/26/202627.02 EUR
2/25/202627.01 EUR
2/23/202627.10 EUR
2/20/202629.24 EUR
2/19/202630.04 EUR
2/18/202629.85 EUR
2/17/202629.12 EUR
2/16/202628.57 EUR
2/13/202628.57 EUR
2/12/202628.21 EUR
2/11/202628.98 EUR
2/10/202629.41 EUR
2/9/202629.25 EUR
2/6/202628.26 EUR
2/5/202628.48 EUR
2/4/202629.36 EUR
2/3/202629.74 EUR
2/2/202629.41 EUR
1/30/202629.96 EUR
1/29/202630.68 EUR
1/28/202631.61 EUR
1/27/202632.38 EUR
1/26/202632.71 EUR
1/23/202632.71 EUR
1/22/202632.49 EUR
1/21/202634.46 EUR
1/20/202632.21 EUR
1/19/202634.19 EUR
1/16/202631.06 EUR
1/15/202631.12 EUR
1/14/202631.67 EUR
1/13/202632.87 EUR
1/12/202633.04 EUR
1/9/202630.90 EUR
1/8/202629.91 EUR
1/7/202628.21 EUR
1/6/202626.84 EUR
1/5/202626.34 EUR
12/30/202528.65 EUR
12/29/202528.59 EUR
12/23/202527.71 EUR
12/22/202527.71 EUR
12/19/202527.38 EUR
12/18/202528.15 EUR
12/17/202527.77 EUR
12/16/202527.49 EUR
12/15/202527.22 EUR
12/12/202527.38 EUR
12/11/202526.95 EUR
12/10/202527.16 EUR
12/9/202527.06 EUR
12/8/202526.78 EUR
12/5/202527.16 EUR
12/4/202527.44 EUR
12/3/202527.55 EUR
12/2/202527.11 EUR
12/1/202527.66 EUR
11/28/202527.77 EUR
11/27/202527.71 EUR
11/26/202527.55 EUR
11/25/202527.44 EUR
11/24/202526.95 EUR
11/21/202526.40 EUR
11/20/202526.01 EUR
11/19/202525.41 EUR
11/18/202524.09 EUR
11/17/202525.41 EUR
11/14/202526.07 EUR
11/13/202526.34 EUR
11/12/202526.12 EUR
11/11/202526.40 EUR
11/10/202525.85 EUR
11/7/202525.63 EUR
11/6/202525.68 EUR
11/5/202526.23 EUR
11/4/202526.95 EUR
11/3/202527.55 EUR
10/31/202528.54 EUR
10/30/202528.10 EUR
10/29/202528.70 EUR
10/28/202527.44 EUR
10/27/202527.44 EUR
10/24/202528.54 EUR
10/23/202528.81 EUR
10/22/202527.16 EUR
10/21/202526.40 EUR
10/20/202525.96 EUR
10/17/202526.18 EUR
10/16/202526.34 EUR
10/15/202526.34 EUR
10/14/202525.96 EUR
10/13/202526.84 EUR
10/10/202526.56 EUR
10/9/202528.10 EUR
10/8/202528.65 EUR
10/7/202528.10 EUR
10/6/202528.54 EUR
10/3/202527.44 EUR
10/2/202526.12 EUR
10/1/202526.12 EUR
9/30/202526.01 EUR
9/29/202525.74 EUR
9/26/202526.01 EUR
9/25/202526.34 EUR
9/24/202526.67 EUR
9/23/202527.44 EUR
9/22/202528.10 EUR
9/19/202528.21 EUR
9/18/202528.65 EUR
9/17/202528.43 EUR
9/16/202527.88 EUR
9/15/202527.77 EUR
9/12/202527.00 EUR
9/11/202527.44 EUR
9/10/202527.99 EUR
9/9/202527.99 EUR
9/8/202528.32 EUR
9/5/202528.54 EUR
9/4/202529.09 EUR
9/3/202529.03 EUR
9/2/202528.65 EUR
9/1/202529.91 EUR
8/29/202529.74 EUR
8/28/202530.68 EUR
8/27/202529.96 EUR
8/26/202530.46 EUR
8/25/202532.05 EUR
8/22/202530.95 EUR
8/21/202530.57 EUR
8/20/202531.67 EUR
8/19/202531.56 EUR
8/18/202531.23 EUR
8/15/202529.85 EUR
8/14/202530.46 EUR
8/13/202528.70 EUR
Access this data via the Eulerpool API
Get Free API Key

PolyPeptide Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
292.92 M EUR
-47.69 M EUR
-48.13 M EUR
Jan 1, 2024
300.50 M EUR
-6.89 M EUR
-18.31 M EUR
Jan 1, 2025
349.56 M EUR
6.94 M EUR
-19.94 M EUR
Jan 1, 2026 (e)
460.27 M EUR
9.84 M EUR
28.93 M EUR
Jan 1, 2027 (e)
531.37 M EUR
11.18 M EUR
51.31 M EUR
Jan 1, 2028 (e)
667.07 M EUR
13.14 M EUR
75.44 M EUR
Jan 1, 2029 (e)
743.40 M EUR
14.64 M EUR
99.60 M EUR
Jan 1, 2030 (e)
818.22 M EUR
16.12 M EUR
107.87 M EUR

PolyPeptide Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 1:43 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
SHARESM
201820192020202120222023202420252026e2027e2028e2029e2030e
168.00189.00209.00263.00280.00299.00316.00366.00460.00531.00667.00743.00818.00
–12.5010.5825.846.466.795.6915.8225.6815.4325.6111.3910.09
34.5234.9232.5435.3618.211.3411.3916.3916.3916.3916.3916.3916.39
58.0066.0068.0093.0051.004.0036.0060.0075.4187.05109.34121.80134.10
26.0031.0041.0060.0016.00-47.00-6.006.009.0011.0013.0014.0016.00
15.4816.4019.6222.815.71-15.72-1.901.641.962.071.951.881.96
22.0024.0029.0044.007.00-48.00-18.00-19.0028.0051.0075.0099.00107.00
–9.0920.8351.72-84.09-785.71-62.505.56-247.3782.1447.0632.008.08
––––0.30–––0.300.300.30––
30.0030.0030.0033.0832.9532.9933.4733.0133.0133.0133.0133.0133.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales PolyPeptide Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PolyPeptide Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PolyPeptide Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares PolyPeptide Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PolyPeptide Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

PolyPeptide Group stock margins

The PolyPeptide Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PolyPeptide Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PolyPeptide Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
35.73 %
23.00 %
16.94 %
Jan 1, 2022
18.98 %
5.85 %
2.84 %
Jan 1, 2023
1.52 %
-16.28 %
-16.43 %
Jan 1, 2024
12.23 %
-2.29 %
-6.09 %
Jan 1, 2025
17.22 %
1.98 %
-5.70 %
Jan 1, 2026 (e)
17.22 %
2.14 %
6.29 %
Jan 1, 2027 (e)
17.22 %
2.10 %
9.66 %
Jan 1, 2028 (e)
17.22 %
1.97 %
11.31 %

PolyPeptide Group Stock Revenue, EBIT, Earnings per Share

The PolyPeptide Group earnings per share therefore indicates how much revenue PolyPeptide Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
7.89 EUR
1.82 EUR
1.34 EUR
Jan 1, 2022
8.31 EUR
0.49 EUR
0.24 EUR
Jan 1, 2023
8.88 EUR
-1.45 EUR
-1.46 EUR
Jan 1, 2024
8.98 EUR
-0.21 EUR
-0.55 EUR
Jan 1, 2025
10.59 EUR
0.21 EUR
-0.60 EUR
Jan 1, 2026 (e)
13.90 EUR
0.30 EUR
0.87 EUR
Jan 1, 2027 (e)
16.04 EUR
0.34 EUR
1.55 EUR
Jan 1, 2028 (e)
20.14 EUR
0.40 EUR
2.28 EUR

PolyPeptide Group business model & stock analysis

PolyPeptide Group AG is a leading company in peptide chemistry and offers customized peptide solutions for a variety of applications to its customers. The company was founded in 1994 and is headquartered in Zurich, Switzerland. PolyPeptide has branches in seven countries and operates worldwide in over 80 countries. The company works with customers from various industries, including the pharmaceutical industry, biotechnology, diagnostics, as well as cosmetics and food industries. With many years of experience, a deep understanding of peptide chemistry, and state-of-the-art technologies, PolyPeptide is able to offer its customers first-class and tailor-made peptide solutions. PolyPeptide is divided into three divisions: Generics, Innovative Peptides, and Peptide Manufacturing. In the Generics division, the company offers a wide range of generic peptides that can be used for various applications. These peptides are manufactured to the highest quality standards and are cost-effective alternatives to expensive proprietary peptides. The Innovative Peptides division offers customized peptide solutions for specific applications. These peptides are developed in close collaboration with customers and can be used for the treatment of cancer, autoimmune diseases, diabetes, and other conditions. The third division, Peptide Manufacturing, specializes in the production of peptides for clinical studies and commercial production. PolyPeptide has modern production facilities and strict quality controls to ensure that the peptides meet the highest quality standards. PolyPeptide's business model is based on close collaboration with customers and partners to develop tailor-made peptide solutions. The company works closely with its customers to understand their requirements and develop suitable peptides for their specific applications. PolyPeptide has an experienced team of scientists and technicians specialized in peptide synthesis and continuously focuses on the latest knowledge in peptide chemistry. PolyPeptide offers a wide range of products, including generic peptides for research purposes, customized peptides for specific applications, peptides for clinical studies, and for commercial production. The company has a wealth of experience in peptide chemistry and has acquired numerous patents for its technologies and methods. In summary, PolyPeptide Group AG is a leading company in peptide chemistry. The company offers customized peptide solutions for a variety of applications and has extensive experience in manufacturing peptides for the pharmaceutical industry, biotechnology, diagnostics, cosmetics, and food industry. Through its close collaboration with customers and state-of-the-art technologies, PolyPeptide is able to offer its customers first-class and cost-effective peptide solutions, solidifying its position as a leader in peptide chemistry.

PolyPeptide Group SWOT Analysis

Strengths

PolyPeptide Group AG has a strong reputation in the biotechnology industry, known for its expertise in peptide manufacturing and synthesis.

The company has an extensive portfolio of high-quality products, providing a competitive advantage over rivals.

PolyPeptide Group AG invests significantly in research and development activities, allowing for continuous innovation and the development of new products.

The company has a global presence, with production facilities and sales offices strategically located in key markets.

Weaknesses

PolyPeptide Group AG may face challenges in maintaining cost competitiveness due to the complex nature of peptide manufacturing processes.

The company's heavy reliance on a few key customers poses a risk, as losing any of these customers could significantly impact revenue.

PolyPeptide Group AG heavily relies on advanced technology and processes in its operations, which may be susceptible to disruptions or obsolescence.

Opportunities

The increasing demand for peptide-based therapeutics provides a growth opportunity for PolyPeptide Group AG to expand its product offerings.

International expansion into emerging markets, where demand for biotechnology products is growing, presents an opportunity for business expansion.

Forming strategic partnerships with pharmaceutical companies or academic institutions can lead to joint research projects and access to new markets.

Threats

Intense competition within the biotechnology industry may pose a threat to PolyPeptide Group AG's market share and profitability.

Regulatory changes and stricter compliance requirements could increase operational costs or impact product development timelines.

Fluctuations in the global economy and currency exchange rates can impact the company's financial performance, particularly in international markets.

PolyPeptide Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

PolyPeptide Group historical P/E ratio, EBIT multiple, and P/S ratio

PolyPeptide Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

PolyPeptide Group shares outstanding

The number of shares of PolyPeptide Group was 33.01 M in 2025. This indicates how many shares PolyPeptide Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
33.08 M Stocks
Jan 1, 2022
32.95 M Stocks
Jan 1, 2023
32.99 M Stocks
Jan 1, 2024
33.47 M Stocks
Jan 1, 2025
33.01 M Stocks
Jan 1, 2026 (e)
33.01 M Stocks
Jan 1, 2027 (e)
33.01 M Stocks
Jan 1, 2028 (e)
33.01 M Stocks

PolyPeptide Group Dividend History

1 years of dividend payments

YearAnnual DividendYoY ChangePayments
20220.30EUR—1×

PolyPeptide Group dividend payout ratio

In 2025, PolyPeptide Group had a payout ratio of 136.25%. The payout ratio indicates the percentage of the company's profits that PolyPeptide Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
136.25 %
Jan 1, 2022
136.25 %
Jan 1, 2023
136.25 %
Jan 1, 2024
136.25 %
Jan 1, 2025
136.25 %
Jan 1, 2026 (e)
34.34 %
Jan 1, 2027 (e)
19.37 %
Jan 1, 2028 (e)
13.17 %

Current PolyPeptide Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
84.62 % (11)
Hold
7.69 % (1)
Sell
7.69 % (1)
12M Price Target
0.00
Last Price
47.04
Currency
EUR
12M Return Potential
-100.00 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the PolyPeptide Group stock

63/100
35
Environment
88
Social
65
Governance
E

Environment

20
Scope 1 - Direct Emissions5,834
Scope 2 - Indirect emissions from purchased energy9,395
Scope 3 - Indirect emissions within the value chain64,667
Total CO₂ emissions15,229
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

PolyPeptide Group shareholder structure

% Name
3.14898%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)
1.74013%
PRIMECAP Management Company
PRIMECAP Management Company
1.64746%
Vontobel Asset Management AG
Vontobel Asset Management AG
1.41005%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.30566%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
0.80596%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG

PolyPeptide Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
39.3%
Float Shares
-
Shares Outstanding
-

PolyPeptide Group Executives and Management Board

11 members · avg. age 61 · 18 % women

JG

Mr. Juan-Jose Gonzalez (53)

Chief Executive Officer

2.54 M EUR

Management

PA

Mr. Patrick Aebischer (71)

Non-Executive Vice Chairman of the Board, Lead Independent Director

224,317.00 EUR
MA

Mr. Marc Augustin (52)

Chief Financial Officer

–
CV

Ms. Christina Del Vecchio (46)

General Counsel, Corporate Secretary

–
MS

Mr. Michael Staheli

Head of Investor Relations and Corporate Communications · since 2020

–

Board of Directors

PW

Mr. Peter Wilden (67)

Non-Executive Chairman of the Board · since 2021

337,042.00 EUR
PW

Dr. Philippe Weber (60)

Non-Executive Independent Director

211,398.00 EUR
BI

Dr. Beat In-Albon (73)

Non-Executive Independent Director

168,641.00 EUR
JS

Ms. Jane Salik (71)

Non-Executive Director · since 2006

140,038.00 EUR
JF

Mr. Jens Fricke (59)

Director Global Operations

–
ES

Mr. Erik Schropp (60)

Non-Executive Director

–

PolyPeptide Group Supply Chain

PolyPeptide Group Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#NameTrend
1
Ultimovacs
Supplier·Customer·Biotechnology·NO
0.83
0.42
0.51
0.75
0.66
—
2
Novavax
Supplier·Customer·Biotechnology·US
0.82
0.12
0.05
0.93
0.77
—
3
Radius Health
Supplier·Customer·Biotechnology·US
0.61
0.83
0.48
0.11
0.39
—
4
CARA Therapeutics
Customer·Pharmaceuticals·US
0.47
0.47
0.63
0.48
0.61
—
5
Windtree Therapeutics
Supplier·Customer·Biotechnology·US
0.08
0.78
0.53
0.84
0.63
—

Frequently asked questions about PolyPeptide Group

The business model of PolyPeptide Group AG, a leading contract manufacturing organization, focuses on producing custom-made peptides and peptide-based drugs for pharmaceutical companies worldwide. With over 60 years of expertise, PolyPeptide offers a comprehensive range of integrated services, including peptide synthesis, manufacturing, and analytical development. By leveraging their state-of-the-art facilities and cutting-edge technologies, the company ensures high-quality standards and regulatory compliance. PolyPeptide's skilled team collaborates closely with clients at every stage of the development process, from research and development to commercial production. Through their dedication to innovation and customer satisfaction, PolyPeptide Group AG strives to be the preferred partner for peptide-based therapeutic solutions.

PolyPeptide Group AG is primarily active in the pharmaceutical industry.

The main competitors of PolyPeptide Group AG in the market include companies such as Bachem Holding AG, Lonza Group Ltd., and CordenPharma International.

PolyPeptide Group AG is a renowned company engaged in the development and manufacturing of peptide-based drugs. Established in [year], PolyPeptide Group AG has emerged as a global leader in this field. With its cutting-edge research and development capabilities, the company has successfully catered to diverse industries, including pharmaceuticals, biotechnology, and cosmetics. PolyPeptide Group AG's commitment to excellence, innovation, and customer satisfaction has helped it forge strong partnerships with leading companies worldwide. Leveraging its extensive expertise, PolyPeptide Group AG continues to revolutionize the peptide industry, driving advancements in therapeutics and creating a meaningful impact on patients' lives globally.

PolyPeptide Group AG has achieved several significant milestones. To begin with, the company successfully expanded its global reach by establishing state-of-the-art production facilities in India and Sweden. Additionally, PolyPeptide Group AG has consistently delivered high-quality peptide-based solutions for pharmaceutical and biotech companies worldwide. The company also received regulatory approvals for several innovative peptide therapeutics, further strengthening its position in the market. Furthermore, PolyPeptide Group AG has collaborated with renowned industry leaders, facilitating the development of cutting-edge therapies. Overall, the company's commitment to innovation, global expansion, and strategic partnerships has led to its remarkable achievements in the field of peptide-based solutions.

PolyPeptide Group AG is primarily present in multiple countries and regions worldwide, ensuring a global reach for its operations. This Swiss-based company has established a strong presence in Europe, with facilities in Belgium, France, Sweden, and Switzerland. Additionally, PolyPeptide Group AG operates in the United States, with manufacturing facilities in California and Scandinavia. The company's broad geographical presence allows it to cater to a diverse client base and strengthen its position as a leading provider of peptide-based solutions in the pharmaceutical and biotech industries.

PolyPeptide Group AG represents a strong commitment to excellence and innovation in the pharmaceutical industry. With a focus on peptide manufacturing, the company strives to deliver high-quality products and services to its customers. PolyPeptide Group AG values scientific expertise, customer satisfaction, and compliance with regulatory standards. Their corporate philosophy emphasizes collaboration, integrity, and sustainable practices. Through their cutting-edge research and development, the company aims to contribute to the advancement of healthcare. By consistently delivering innovative peptide solutions, PolyPeptide Group AG has established itself as a trusted leader in the industry.

Analysts currently set an average price target of 39.62 EUR for the PolyPeptide Group stock (median: 39.85 EUR), implying -15.8 % versus the latest price. The consensus is based on 13 analyst ratings.

PolyPeptide Group Analyst Price Targets 2026

13 analysts currently rate the PolyPeptide Group stock: 11 recommend buying, 1 holding and 1 selling. For 2026, analysts expect PolyPeptide Group to generate revenue of 460.27 M EUR and earnings per share of 0.88 EUR.

PolyPeptide Group Analyst Price Targets 2026

The PolyPeptide Group share (PPGN.SW) is listed on 3 stock exchanges, including: London (0AAJ.L), London (0AAJ.L), SIX (Zürich) (PPGN.SW).

The PolyPeptide Group AG is an internationally active company based in Switzerland. Founded in 1952, it specializes in the production of peptides and proteins for the pharmaceutical industry. PolyPeptide's business model is based on the production and marketing of pharmaceutical peptides and proteins for clinical applications and research. The company offers its customers a wide range of products and services, including: - Synthetic production of peptides and proteins for the pharmaceutical industry. - Research services for the development of peptide-based drugs and diagnostics. - Custom manufacturing of peptides and proteins for research and development. - Production of therapeutic peptides and proteins for clinical applications. To provide these services, PolyPeptide operates production facilities in Sweden, France, India, and the United States. These locations allow the company to quickly respond to the needs of its customers and offer the best solutions for their specific requirements. PolyPeptide's divisions can be described as follows: - Pharmaceutical Peptides: PolyPeptide produces pharmaceutical peptides for clinical applications. This includes drugs for the treatment of cancer, diabetes, autoimmune diseases, and infectious diseases. - Research Peptides: PolyPeptide supplies peptides for research and development of drugs and diagnostics. These peptides allow the research community to gain new insights into molecular processes in the body. - Custom Peptides: The company manufactures custom peptides for research and development. This service is aimed at customers in science and industry who need tailored peptides for their specific applications. - Manufacturing of Therapeutic Proteins: PolyPeptide is a leading provider of therapeutic proteins and peptides for the pharmaceutical industry. This includes drugs for the treatment of cancer, neurological disorders, and metabolic diseases. PolyPeptide focuses on developing innovative peptides and proteins for the pharmaceutical industry. Through continuous research and development and collaboration with industry customers, the company is able to offer its customers the latest products and services. In addition, PolyPeptide emphasizes quality and reliability. All products are manufactured according to the highest quality standards and undergo strict controls. This gives customers the assurance that they will always receive products of the highest quality. Conclusion: The PolyPeptide Group AG is a leading provider of peptides and proteins for the pharmaceutical industry. With its wide range of products and its focus on innovation, quality, and reliability, PolyPeptide is a trusted partner for its customers in the industry and the scientific community.

The expected revenue of PolyPeptide Group is 460.27 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PolyPeptide Group is 28.93 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PolyPeptide Group is currently 53.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PolyPeptide Group stock.

The price-to-sales ratio (P/S) of PolyPeptide Group is currently 3.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PolyPeptide Group stock.

The Eulerpool Quality Score for PolyPeptide Group is 2/10.

The ISIN of PolyPeptide Group is CH1110760852. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of PolyPeptide Group is PPGN.SW. The ticker symbol is used to trade PolyPeptide Group shares on the stock exchange.

Over the past 12 months, PolyPeptide Group paid a dividend of 0.30 EUR . This corresponds to a dividend yield of about 0.64 %. For the coming 12 months, PolyPeptide Group is expected to pay a dividend of 0.30 EUR.

The current dividend yield of PolyPeptide Group is 0.64 %.

PolyPeptide Group paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.30 EUR are expected. This corresponds to a dividend yield of 0.64 %.

PolyPeptide Group is assigned to the 'Health' sector.

To receive the latest dividend of PolyPeptide Group from amounting to 0.3 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of PolyPeptide Group are distributed in EUR.

All fundamentals and in-depth analysis of PolyPeptide Group

Our stock analysis for PolyPeptide Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PolyPeptide Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

PolyPeptide Group Stock
PolyPeptide Group Revenue→
PolyPeptide Group Stock
PolyPeptide Group Net Income→
PolyPeptide Group Stock
PolyPeptide Group P/E→
PolyPeptide Group Stock
PolyPeptide Group P/S→
PolyPeptide Group Stock
PolyPeptide Group EBIT→
PolyPeptide Group Stock
PolyPeptide Group Dividend→
PolyPeptide Group Stock
PolyPeptide Group Directors Dealings→
PolyPeptide Group Stock
PolyPeptide Group Stocks→
PolyPeptide Group Stock
PolyPeptide Group Market capitalization→
PolyPeptide Group Stock
PolyPeptide Group Debt→
PolyPeptide Group Stock
PolyPeptide Group Liabilities→
PolyPeptide Group Stock
PolyPeptide Group Equity→
PolyPeptide Group Stock
PolyPeptide Group AAQS→
PolyPeptide Group Stock
PolyPeptide Group Employees→
PolyPeptide Group Stock
PolyPeptide Group ROE→
PolyPeptide Group Stock
PolyPeptide Group ROA→
PolyPeptide Group Stock
PolyPeptide Group ROCE→
PolyPeptide Group Stock
PolyPeptide Group News→
PolyPeptide Group Stock
PolyPeptide Group Analyst Price Targets→

Health Stocks

PolyrizonPolynovoPOMDOCTOR LIMITED American Depositary SharesPolylite Taiwan CoPoniard PharmaceuticalsPoly MedicurePoolbeg PharmaPolaryx Therapeutics, Inc. Common StockPorton Pharma SolutionsPolaris Group LLCPositronPolaris AI PharmaAll Stocks A–Z →